Lisata Therapeutics Inc./$LSTA
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Ticker
$LSTA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
26
ISIN
US1280583022
Website
LSTA Metrics
BasicAdvanced
$23M
-
-$2.30
1.03
-
Price and volume
Market cap
$23M
Beta
1.03
52-week high
$3.07
52-week low
$1.87
Average daily volume
14K
Financial strength
Current ratio
7.517
Quick ratio
6.983
Total debt to equity
0.367
Profitability
EBITDA (TTM)
-21.484
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,930.80%
Operating margin (TTM)
-2,165.50%
Effective tax rate (TTM)
4.75%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-35.05%
Return on equity (TTM)
-56.92%
Valuation
Price to revenue (TTM)
22.024
Price to book
0.89
Price to tangible book (TTM)
0.9
Price to free cash flow (TTM)
-1.24
Free cash flow yield (TTM)
-80.64%
Free cash flow per share (TTM)
-211.27%
Growth
Earnings per share change (TTM)
-6.66%
10-year revenue growth (CAGR)
-24.70%
3-year earnings per share growth (CAGR)
-27.04%
10-year earnings per share growth (CAGR)
-37.63%
LSTA News
AllArticlesVideos
Lisata Therapeutics reports encouraging data from ASCEND Cohort B evaluating certepetide in pancreatic cancer
Proactive Investors·1 week ago
Lisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC Health
Proactive Investors·3 weeks ago
Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lisata Therapeutics Inc. stock?
Lisata Therapeutics Inc. (LSTA) has a market cap of $23M as of July 05, 2025.
What is the P/E ratio for Lisata Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Lisata Therapeutics Inc. (LSTA) stock is 0 as of July 05, 2025.
Does Lisata Therapeutics Inc. stock pay dividends?
No, Lisata Therapeutics Inc. (LSTA) stock does not pay dividends to its shareholders as of July 05, 2025.
When is the next Lisata Therapeutics Inc. dividend payment date?
Lisata Therapeutics Inc. (LSTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Lisata Therapeutics Inc.?
Lisata Therapeutics Inc. (LSTA) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.